-
Security Type
-
Preferred Stock
-
Min Investment
-
$251
-
Offering Date
-
January 15, 2021
-
Expected Close Date
-
October 31, 2022
-
Target Raise
-
$100.00K-$5.00M
-
No. Investors
-
14
-
Security Price
-
$10.01
-
Valuation
-
$89,900,000
- Number of Employees
- 20
- Cash
- $5,535,710
- Revenue
- $628,246
- Short Term Debt
- $0
- Cost of Goods
- $458,675
- Long Term Debt
- $0
- Net Income
- $-11,814,968
Company Description
Monogram is a medical technology company ushering in the future of joint reconstruction. Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms. We are designing our state-of-the-art surgical robot with the aim of mitigating the risks of poor placement, fracture, and subsidence to give surgeons confidence that they can install implants that fit every patient - perfectly.
Perks
$5,000+ Investment
5% Bonus Shares
Invest $5,000 and receive 5% Bonus Shares on your investment
$10,000+ Investment
10% Bonus Shares
Invest $10,000 and receive 10% Bonus Shares on your investment
Key Deal Facts
World-class team with a track record of execution: led by a team of experts in robotics and medical technology, and advised by surgeon consultants from institutions such as Columbia and Icahn School of Medicine.
First revenues in 2021 & new product launches: we have generated our first revenue in 2021 and expect to launch our first-gen implants during the first half of 2022.
Already raised $16.7M from 6,793 investors: We have been through 3 successful financing rounds and continue to execute.
Established product-market fit: the leading orthopedic robot on the market (technology from a startup acquired in 2013) outsells its next largest competitor over 12-to-1 with an 87% share. We understand its limitations and have the team to build the future of robotics.
Novel technology for massive growing market: The joint replacement market is approximately $19.6BN, with over 1 million knee replacements per year. We believe we will be one of the first to market with our technology and eight patent filings.
Winner of award from National Science Foundation (NSF): Recipient of SBIR Phase I award for "Development of a tracking system for computer-assisted surgery."